About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
OMER - Omeros Corporation| Previous Close | $10.46 | Open | $10.48 |
| Volume | 477.8K | Market Cap | 904.14M |
| Yield | Last Dividend |
| Omeros Participates in Investor Conferen... | 10/28/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced that results from its compassionate use study evaluating narsoplimab in COVID-19... | |
| Global Opioid Use Disorder Market (Covid... | 10/22/20 |
| Data Bridge Market Research has recently added a concise research on the Global Opioid Use Disorder Market- Industry Trends and Forecast to 2026. A re... | |
| Omeros (NASDAQ:OMER) Earns Buy Rating fr... | 10/20/20 |
| Analysts at Bank of America started coverage on shares of Omeros (NASDAQ:OMER) in a report issued on Tuesday, The Fly reports. The firm set a ???buy??... | |
| Omeros??? OMS906 Data Presented at Compl... | 10/16/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Developm... | |
| Omeros Schedules Webcast to Present Fina... | 10/15/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the final results of its pivotal trial of narsoplimab in the treatmen... | |
| Omeros Provides Update on Separate Payme... | 10/01/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today provided an update on the status of reimbursement for its cataract surgery drug OMID... | |
| Omeros to Present at the Cantor Virtual ... | 09/11/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, wil... | |
| Omeros??? Investigational New Drug Appli... | 08/31/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that its Investigational New Drug Application (IND) to begin clinical trials with OMS906 ... | |
| The Daily Biotech Pulse: Regulatory Setb... | 08/11/20 |
| Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Allovir Inc (NASDAQ: ALVR ) BioLife Solutions Inc (NASDAQ: BLFS ) BioSpecifics Techno... | |
| Omeros EPS misses by $0.02, misses on re... | 08/10/20 |
| Omeros (NASDAQ:OMER): Q2 GAAP EPS of -$0.61 misses by $0.02. Revenue of $13.53M (-49.4% Y/Y) misses by $3.57M. Press Release | |
| Omeros Announces Proposed Public Offerin... | 08/10/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) (???Omeros???) today announced that it has commenced concurrent underwritten public offeri... | |
| Omeros Corporation Reports Second Quarte... | 08/10/20 |
| Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecul | |
| Omeros Rallies On COVID-19 Study Results... | 08/10/20 |
| Omeros Corporation (NASDAQ: OMER ) shares were galloping higher Monday after the biopharma announced results from a compassionate use study of its lea... | |
| Drug developer Omeros reports positive r... | 08/10/20 |
| Omeros said all six patients, who needed mechanical ventilation before treatment, recovered and were discharged from hospital | |
| Omeros : reports full recovery from seve... | 08/10/20 |
| Omeros Corp on Monday reported positive results from a six-patient study of its investigational treatment for Acute Respiratory Distress Syndrome caus... | |
| Omeros Corporation Reports Recovery and ... | 08/10/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today reported the results of a compassionate-use study evaluating narsoplimab, Omeros??? ... | |
| Omeros??? Narsoplimab Pivotal Trial Data... | 06/12/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of h... | |
| Omeros??? Narsoplimab Pivotal Trial Data... | 06/11/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER): The results of Omeros??? pivotal trial of narsoplimab for the treatment of hematopoietic ... | |
| Omeros Corporation Announces Presentatio... | 05/14/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of h... | |
| Should You Buy Omeros (OMER) Ahead of Ea... | 05/08/20 |
| Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. | |
| Omeros Corporation to Announce First Qua... | 05/05/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the p... | |
| Omeros Corporation Reports Fourth Quarte... | 03/02/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and com... | |
| Omeros Corporation Reports Updated Resul... | 03/02/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today reports an update on clinical data from its pivotal trial of narsoplimab in the trea... | |
| Omeros Corporation to Announce Fourth Qu... | 02/24/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end 2019 financial... | |
| Omeros Corporation Appoints Former Amazo... | 02/11/20 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced the appointment of Kurt Zumwalt, former global treasurer of Amazon.com, In... | |
| The Daily Biotech Pulse: EyePoint In-Lic... | 02/04/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Ac... | |
| 2019 Glomerulonephritis Pipeline Review,... | 01/09/20 |
| DUBLIN--(BUSINESS WIRE)--The "Glomerulonephritis - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Glome... | |
| myTomorrows and Omeros Corporation Colla... | 12/18/19 |
| AMSTERDAM & SEATTLE--(BUSINESS WIRE)--myTomorrows, a global health technology company, and Omeros Corporation (Nasdaq: OMER), an innovative biopharmac... | |
| Omeros??? Newly Presented GPR174 Immuno-... | 12/16/19 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) last week presented new data directed to its novel cancer immunotherapy target GPR174 at t... | |
| Omeros Announces Full Exercise and Closi... | 12/13/19 |
| SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) (???Omeros???), a commercial-stage biopharmaceutical company committed to discovering, dev... | |
| Buy rating | 10/20/20 |
| B of A Securities initiates coverage with Buy rating and announces Price Target of $21.00 | |
| Hold rating | 09/01/20 |
| Wedbush maintains Neutral rating and lowers Price Target from $17.00 to $12.00 | |
| Buy rating | 08/21/20 |
| HC Wainwright & Co. maintains Buy rating and lowers Price Target from $34.00 to $32.00 | |
| Date | 2020-08-10 (AMC) | Est. (EPS/Rev.) | ($0.64)/ 14.65M |
| Actual (EPS/Rev.) | $-0.61/ $13.53 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Bye Bye Patron | Bye bye patron | 83.00 % | Follow |
| Tech Trades | Tech Trades | 82.00 % | Follow |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Burdeshaw Investing | Matthew Burdeshaw | 55.00 % | Subscribe |
| Biotech picks | mr jackson | 50.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
